New drug combo aims to control Hard-to-Treat leukemia
NCT ID NCT05038592
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study tests a combination of two drugs—tagraxofusp and decitabine—in people with chronic myelomonocytic leukemia or high-risk myelodysplastic syndromes. Tagraxofusp is a targeted therapy that delivers a toxin to cancer cells, while decitabine is a chemotherapy drug. The trial aims to find the safest dose and see if the combination can shrink or control the cancer. It includes 64 adults whose disease has not responded well to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tagraxofusp and decitabine
What this could lead to
If this combination works, it could offer a new treatment option for people with certain blood cancers that are hard to treat.
What could go wrong
This is an early-phase trial with only 64 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the treatment may not shrink tumors in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.